naproxen has been researched along with celecoxib in 201 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (celecoxib) | Trials (celecoxib) | Recent Studies (post-2010) (celecoxib) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 5,273 | 843 | 2,428 |
| Protein | Taxonomy | naproxen (IC50) | celecoxib (IC50) |
|---|---|---|---|
| Chain A, Carbonic anhydrase II | Homo sapiens (human) | 0.021 | |
| Prostaglandin E synthase | Homo sapiens (human) | 0.4825 | |
| Histone deacetylase 3 | Homo sapiens (human) | 1.637 | |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 7.9667 | |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.057 | |
| Cytochrome c oxidase subunit 1 | Ovis aries (sheep) | 6.5 | |
| Cytochrome c oxidase subunit 2 | Ovis aries (sheep) | 0.0881 | |
| Catechol O-methyltransferase | Mus musculus (house mouse) | 0.036 | |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 0.371 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 0.1555 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.0925 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 5.271 | |
| Procathepsin L | Homo sapiens (human) | 0.56 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 7.308 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 0.07 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 4.295 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 10 | |
| Calpain-2 catalytic subunit | Homo sapiens (human) | 0.002 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 1.516 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.12 | |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | 3.6401 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 3.5499 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 7.308 | |
| Indoleamine 2,3-dioxygenase 1 | Mus musculus (house mouse) | 0.006 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 6.276 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.3818 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.4028 | |
| Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 7.6 | |
| Histone deacetylase 4 | Homo sapiens (human) | 1.637 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.03 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.6343 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 7.7 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.431 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.045 | |
| Histone deacetylase 1 | Homo sapiens (human) | 1.411 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.81 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 0.016 | |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | 0.05 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.3 | |
| Prostaglandin G/H synthase 1 | Canis lupus familiaris (dog) | 5.57 | |
| Cyclooxygenase-2 | Canis lupus familiaris (dog) | 0.9 | |
| Histone deacetylase 7 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 2 | Homo sapiens (human) | 1.637 | |
| Carbonic anhydrase 4 | Bos taurus (cattle) | 0.2227 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 11 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 8 | Homo sapiens (human) | 1.637 | |
| P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | 0.04 | |
| Histone deacetylase 6 | Homo sapiens (human) | 1.14 | |
| Histone deacetylase 9 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 5 | Homo sapiens (human) | 1.637 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (3.48) | 18.2507 |
| 2000's | 92 (45.77) | 29.6817 |
| 2010's | 89 (44.28) | 24.3611 |
| 2020's | 13 (6.47) | 2.80 |
| Authors | Studies |
|---|---|
| Bertenshaw, SR; Burton, EG; Carter, JS; Cogburn, JN; Collins, PW; Docter, S; Graneto, MJ; Gregory, SA; Isakson, PC; Koboldt, CM; Lee, LF; Malecha, JW; Miyashiro, JM; Penning, TD; Perkins, WE; Rogers, RS; Rogier, DJ; Seibert, K; Talley, JJ; Veenhuizen, AW; Yu, SS; Zhang, YY | 1 |
| Beleta, J; Cardelús, I; Crespo, MI; Feixas, J; Godessart, N; Heredia, A; Huerta, JM; Ibarzo, J; Jiménez, JM; López, M; Miralpeix, M; Palacios, JM; Puig, C; Puig, J; Ryder, H; Segarra, V; Soca, L | 1 |
| Bedard, PW; Camphausen, RT; DeBernardo, S; Janz, K; Kaila, N; Keith, JC; Nickerson-Nutter, C; Shilling, A; Tam, S; Tsao, DH; Wang, Q; Young-Sciame, R | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Anderluh, M; Brunskole, M; Gobec, S; Lanisnik Rizner, T; Stefane, B; Stojan, J; Zorko, K | 1 |
| Abraham, WM; Albert, L; Behnke, ML; Chen, L; Clark, JD; Donahue, F; Foley, MA; Goodwin, DG; Hegen, M; Hu, B; Hu, Y; Ipek, M; Keith, J; Kirincich, SJ; Ku, MS; Lee, KL; McKew, JC; Michalak, R; Murphy, EA; Nickerson-Nutter, CL; Ramarao, MK; Shen, MW; Sum, FW; Tam, S; Thakker, P; Thomason, J; Williams, C; Wooder, L; Wu, K; Xu, X | 1 |
| Chen, L; Clark, JD; Goodwin, DG; Lee, KL; McKew, JC; Murphy, EA; Nickerson-Nutter, C; Shen, MW; Tam, S; Wang, W; Xu, X; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chaudhaery, SS; Eleftheriou, P; Filimonov, D; Filz, O; Geronikaki, A; Hadjipavlou-Litina, D; Poroikov, V; Roy, KK; Saxena, AK; Vicini, P | 1 |
| Bhardwaj, A; Huang, Z; Kaur, J; Knaus, EE; Sharma, SK; Wuest, F | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ameen, BAH; Dissanayake, AA; Nair, MG | 1 |
| Boixareu, N; Campanera, JM; Navarro, L; Pors, K; Pouplana, R; Pujol, MD; Rosell, G; Sánchez, S | 1 |
| Geis, GS; Hubbard, RC; Isakson, PC; Lanza, FL; Lipsky, PE; Schwartz, BD; Simon, LS; Talwalker, S | 1 |
| Gierse, JK; Isakson, PC; Koboldt, CM; Seibert, K; Walker, MC | 1 |
| Brunner, HR; Burnier, M; Maillard, M; Nussberger, J; Rossat, J | 1 |
| Bensen, WG; Fiechtner, JJ; Geis, GS; Hubbard, RC; Isakson, PC; McMillen, JI; Verburg, KM; Woods, EM; Yu, SS; Zhao, WW | 1 |
| Geis, GS; Graham, DY; Hubbard, RC; Isakson, PC; Kivitz, AJ; Lipsky, PE; Simon, LS; Verburg, KM; Weaver, AL; Yu, SS; Zhao, WW | 1 |
| Wallace, JL | 1 |
| Asfaha, S; McKnight, W; Muscará, MN; Wallace, JL | 1 |
| Megeff, CE; Strayer, SM | 1 |
| Drower, EJ; Geis, GS; Isakson, PC; Schulman, G; Verburg, KM; Wallemark, C; Whelton, A | 1 |
| Agrawal, NM; Bensen, WG; Burke, TA; Geis, GS; Makuch, RW; Maurath, CJ; Zabinski, RA; Zhao, SZ | 1 |
| Bensen, WG | 1 |
| Dedhiya, SD; Espinoza, L; Lisse, J; Osterhaus, JT; Zhao, SZ | 1 |
| Tive, L | 1 |
| Burr, AM; Correa, P; Geis, GS; Goldstein, JL; Hubbard, RC; Verburg, KM; Zhao, WW | 1 |
| Bai, JC; Mauriño, E; Meddings, J; Niveloni, S; Pedreira, S; Smecuol, E; Sugai, E; Vazquez, H | 1 |
| Browning, RA; Burgess, FW | 1 |
| Deray, G | 1 |
| Chandra, A; Nair, MG; Schutzki, R; Seeram, NP | 1 |
| Clifford, LJ; Dewitt, DL; Nair, MG; Rana, J | 1 |
| Brune, K; Gertz, BJ; Gottesdiener, KM; Holmes, GB; Kalyani, RN; Lasseter, KC; Laurenzi, M; Malice, MP; Redfern, KJ; Schwartz, JI; Vandormael, K | 1 |
| Helmuth, L | 1 |
| Arbogast, PG; Daugherty, JR; Griffin, MR; Hall, K; Ray, WA; Stein, CM | 1 |
| Anderson, GM; Austin, PC; Juurlink, DN; Kopp, A; Laupacis, A; Mamdani, M; Naglie, G; Rochon, P | 1 |
| Breitner, JC | 1 |
| Boulet, J; Gottshall, S; Harrison, J; Mark, L; Pearson, M; Walker, K; Whiteside, GT | 1 |
| Harley, C; Wagner, S | 1 |
| Dedhiya, SD; Fiechtner, JI; Osterhaus, JT; Tindall, EA; Yu, SS; Zhao, SZ; Zhao, WW | 1 |
| Burian, M; Geisslinger, G | 1 |
| Mastalerz, L; Radziszewski, W; Setkowicz, M; Szczeklik, A; Zembowicz, A | 1 |
| Burke, TA; Goldstein, JL; Henderson, SC; Palmer, R; von Allmen, H; Zhao, SZ | 1 |
| Burke, TA; Michaud, K; Wolfe, F; Zhao, SZ | 1 |
| Cryer, B; Kimmey, MB; Riff, DS; Rothstein, RI; Scheiman, JM; Wolfe, MM | 1 |
| Behm, A; Cox, ER; Fairman, KA; Frisse, M | 1 |
| Ekman, EF; Fort, JG; Petrella, R; Schuller, R | 1 |
| Cui, H; Hufman, SL; Petri, M; Snabes, MC; Verburg, KM; Waser, G | 1 |
| Cirino, G; Di Lorenzo, A; Farneti, S; Fiorucci, S; Morelli, A; Renga, B | 1 |
| Dionne, RA; Ta, LE | 1 |
| Chen, LS; Chen, SC; Chen, WJ; Hou, SM; Lai, MS; Wang, CT; Yen, ZS | 1 |
| Chan, WS; Cheung, SH; Kwong, KS; Leung, SP | 1 |
| Fitzgerald, GA | 1 |
| Dahlborg, R; Day, CA; Jacob, RF; Mason, RP; Walter, MF; Weng, Y | 1 |
| Brabant, T; Fort, JG; Kivitz, A; Pitt, B; Simon, LS; Sowers, JR; van Ingen, H; Whelton, A; White, WB; Winer, N | 1 |
| Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL | 1 |
| Eisen, GM; Fort, JG; Goldstein, JL; Gralnek, IM; Lewis, B; Zlotnick, S | 1 |
| Arroyo, V; Clària, J; Escolar, G; Ginès, P; Jiménez, W; Kent, JD; López-Parra, M; Ruiz-Del-Arbol, L; Vucelic, B | 1 |
| Chiou, CF; Ofman, JJ; Spiegel, BM | 1 |
| Pearson, RL | 1 |
| Campbell, MS; Makar, GA | 1 |
| Scheiman, JM | 1 |
| Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM | 1 |
| Burnier, M; Mathieu, C; Meier, P; Meyer zu Starten, A | 1 |
| Couzin, J | 1 |
| Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD | 1 |
| Agrawal, NM; Andrade-Ortega, L; Bello, AE; Eisen, GM; Fort, JG; Goldstein, JL; Hanrahan, PS; Levy, RA; Singh, G; Stenson, WF; Triadafilopoulos, G; Wallemark, C | 1 |
| Baraliakos, X; Bohl-Bühler, MH; Braun, J; Feldtkeller, E; Zochling, J | 1 |
| Kandefer-Szerszeń, M; Majdan, M; Parada-Turska, J; Rzeski, W; Turski, WA | 1 |
| Geisslinger, G; Tegeder, I | 1 |
| Dodge, WE; Goldstein, JL; Lanza, FL; Lowry, SC; Schwartz, HI | 1 |
| Barner, JC; Busti, AJ; Lawson, KA; Motsko, SP; Rascati, KL; Wilson, JP; Worchel, J | 1 |
| Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C | 1 |
| Henry, D; McGettigan, P | 1 |
| Brookhart, MA; Rassen, J; Schneeweiss, S; Solomon, DH; Wang, PS | 1 |
| Deray, G; Montalescot, G; Sibilia, J | 1 |
| Hilário, MO; Len, CA; Terreri, MT | 1 |
| Nedjar, H; Rahme, E | 1 |
| Ashcroft, DM; Chen, LC | 1 |
| Breitner, JC; Green, RC; Lyketsos, CG; Martin, BK; Meinert, C; Piantadosi, S; Sabbagh, M | 1 |
| Jacobs, P; Loyd, M; Rublee, D | 1 |
| Aisenberg, J; Berger, MF; Dodge, WE; Goldstein, JL; Zakko, SF | 1 |
| Andriulli, A; Colaizzo, D; Dallapiccola, B; Di Mario, F; Franceschi, M; Grandone, E; Leandro, G; Niro, V; Pilotto, A; Scarcelli, C; Seripa, D | 1 |
| Geisslinger, G; Graff, J; Harder, S; Klinkhardt, U; Nüsing, RM; Seyberth, H; Skarke, C; Watzer, B | 1 |
| Amer, F; Cryer, B; Goldstein, JL; Hunt, B | 1 |
| Gertz, BJ; Gottesdiener, KM; Hilliard, DA; Hreniuk, D; Lasseter, KC; Miller, J; Schwartz, JI; Snyder, KM; Thach, C | 1 |
| Andrade, SE; Boudreau, D; Brown, JS; Chan, KA; Davis, RL; Graham, D; Gunter, MJ; Gurwitz, JH; Herrinton, L; Kulldorff, M; Pettus, PT; Platt, R; Raebel, MA; Roblin, D; Smith, D | 1 |
| El Masry, MA; Gamie, Z; Macfarlane, RJ; Ng, BH; Schizas, C; Tsiridis, E; Velonis, S | 1 |
| Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J | 1 |
| Brandt, J; Breitner, JC; Craft, S; Evans, D; Green, R; Martin, BK; Mullan, M; Piantadosi, S; Szekely, C | 1 |
| Buyse, M; Farinotti, R; Zrieki, A | 1 |
| Banerjee, S; Brilakis, ES; Cryer, B; Cunningham, F; Harford, WV; Kazi, S; Kelly, KC; Little, BB; Warner, JJ; Weideman, RA | 1 |
| Bloom, BJ; Foeldvari, I; Giannini, EH; Krishnaswami, S; Lovell, DJ; Robbins, JL; Steidle, G; Szer, IS; West, CR; Zemel, LS | 1 |
| Aisenberg, J; Bamji, N; Bodian, C; Brooks, A; Cohen, L; Desai, J; Dikman, A; Miller, K; Sanyal, S; VON Althann, C; Whitson, M | 1 |
| Damkier, P; Larsen, TB; Schjerning, O | 1 |
| Bandi, S; Enami, Y; Gupta, S; Joseph, B; Kapoor, S; Krohn, N | 1 |
| Breitner, JC; McCaffrey, LD; Meinert, CL | 1 |
| Becker, MC; Borer, JS; Graham, DY; Husni, ME; Krum, H; Libby, P; Lincoff, AM; Lüscher, TF; Mascette, AM; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, TH; Wisniewski, L; Wolski, K; Yeomans, ND | 1 |
| Bregman, N; Karni, A; Korczyn, AD | 1 |
| Daniels, S; Nemeth, MA; Robbins, J; West, CR | 1 |
| Benhamou, M; Dougados, M; Gossec, L | 1 |
| Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C | 1 |
| Horn, TL; Johnson, WD; Lubet, RA; McCormick, DL; Phillips, JM; Steele, VE | 1 |
| Han, CD; Kim, YH; Lee, JW; Paik, S; Yoo, JH; Yoon, DS | 1 |
| Baker, LD; Breitner, JC; Milne, G; Montine, TJ; Sonnen, JA | 1 |
| Choy, EH; Gaugris, S; Jansen, JP; Nash, JT; Ostor, A; Stam, W | 1 |
| Adrahtas, A; Bertucci, MC; Cheung, RY; Krum, H; Ma, JY; Wang, BH | 1 |
| Bianchi, C; Burgess, TA; Chu, LM; Feng, J; Laham, RJ; Robich, MP; Sellke, FW | 1 |
| Fort, JG; Hochberg, MC; Hwang, C; Sostek, M; Svensson, O | 1 |
| Breitner, JC; Leoutsakos, JM; Lyketsos, CG; Muthen, BO | 1 |
| Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ | 1 |
| Bercik, P; Bolla, M; Collins, SM; de Palma, G; Denou, E; Jury, J; McKnight, W; Ongini, E; Syer, S; Verdu, E; Vong, L; Wallace, JL | 1 |
| Drye, L; Fields, C; Lyketsos, C; Vaidya, V | 1 |
| Ashe, KH; Baker, LD; Brandt, J; Breitner, JC; Craft, S; Evans, DE; Green, RC; Ismail, MS; Lyketsos, CG; Martin, BK; Meinert, CL; Montine, TJ; Mullan, MJ; Sabbagh, M; Tariot, PN | 1 |
| Cryer, BL; Fort, JG; Hochberg, MC; Hwang, C; Sostek, MB; Svensson, O | 1 |
| Bianchi, C; Burgess, T; Chu, LM; Feng, J; Liu, Y; Robich, MP; Sellke, FW; Xu, SH | 1 |
| Blackler, R; Bolla, M; Ongini, E; Syer, S; Wallace, JL | 1 |
| Bhadra, P; Essex, MN; Sands, GH | 1 |
| Aljadhey, H; Blalock, SJ; Brater, DC; Hansen, RA; Murray, MD; Tu, W | 1 |
| Bansal, M; Happich, M; Klein, R; Wielage, R; Wilson, K | 1 |
| Bhadra Brown, P; Essex, MN; O'Connell, M | 1 |
| Chandra, C; Chandy, SJ; Danda, D; Iliyas, MM; Mathew, AJ | 1 |
| Brandt, J; Breitner, JC; Luis, CA; Martin, B; Reckess, GZ; Zandi, P | 1 |
| Bartlett, AL; Forrester, SN; Leoutsakos, JM; Lyketsos, CG | 1 |
| Dong, L; Jurban, BJ; Sharma, NP; Smith, WL | 1 |
| Aneja, A; Farkouh, ME; Gandhi, S; Greenberg, J; Iyengar, RL; Mosovich, S; Razzouk, L; Thorpe, K | 1 |
| Sifferlin, A | 1 |
| Chang, HY; Chen, DY; Cheng, HD; Chiang, EP; Chih, HM; Huang, ST; Lan, JL; Tang, FY | 1 |
| Bhardwaj, A; Kaur, J; Knaus, EE; Wuest, F | 1 |
| Kuentz, M; Niederquell, A | 1 |
| Brown, MT; Ekman, EF; Greenberg, HS; Schnitzer, TJ; Smith, MD; Spierings, EL; Verburg, KM; West, CR | 1 |
| Beshay, JE; Levy, M; Madden, CJ; Rickert, KL; Sarode, R; Scott, WW | 1 |
| Ariano, C; Baldi, C; Cantatrione, S; Cioppa, C; De Vecchis, R; Di Biase, G; Giasi, A; Valente, L | 1 |
| Biletska, L; Bondarchuk, T; Fomenko, I; Panasyuk, N; Sklyarov, A; Wallace, JL | 1 |
| Bannuru, RR; Kent, DM; McAlindon, TE; Schmid, CH; Vaysbrot, EE; Wong, JB | 1 |
| Aguilar, MI; Benítez, WV; Bye, R; Calzada, F; Colín, A; Ríos-Gómez, R | 1 |
| Bao, W; Behar, R; Essex, MN; O'Connell, MA | 1 |
| Di Franco, M; Frati, L; Guarino, ML; Guzzo, MP; Massimi, I; Pulcinelli, FM; Temperilli, F; Valesini, G | 1 |
| Bello, AE; Fort, JG; Grahn, AY; Holt, RJ; Kent, JD | 1 |
| Collins, JE; Hunter, DJ; Jordan, JM; Katz, JN; Losina, E; Paltiel, AD; Smith, SR; Solomon, DH; Suter, LG; Yelin, E | 1 |
| Matteson, EL; Thongprayoon, C; Ungprasert, P | 1 |
| Choi, SJ; Ji, JD; Kim, JH; Lee, YH; Seo, YH; Song, GG | 1 |
| Mackenzie, LS; Patel, P; Perez-Diaz, N; Tang, L; Zloh, M | 1 |
| Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND | 1 |
| González-Gay, MA; González-Juanatey, C | 1 |
| Nurmohamed, MT | 1 |
| Grosser, T | 1 |
| Nissen, SE | 1 |
| Raschle, J | 1 |
| Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY | 1 |
| McGettigan, P; Olsen, AS | 1 |
| Onuora, S | 1 |
| Marin, A; Markotic, F; Puljak, L; Tugwell, P; Utrobicic, A; Vrdoljak, D | 1 |
| Nitschmann, S; Schrör, K | 1 |
| Hyun, MK; Woo, Y | 1 |
| Ganju, J; Rom, D | 1 |
| Baek, JS; Lee, YH; Loo, SCJ; Tan, NS; Yeo, EW | 1 |
| Borer, JS; Brennan, DM; Husni, ME; Libby, PA; Lincoff, AM; Lϋscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wisniewski, LM; Yeomans, ND | 1 |
| Anderson, B; Cooper, TE; Eccleston, C; Fisher, E; Wilkinson, NM | 1 |
| Chan, N; Weitz, J | 1 |
| Breivik, H | 1 |
| Gislason, G; Sondergaard, KB | 1 |
| Beckerman, B; Borer, JS; Davey, DA; Fayyad, R; Flammer, AJ; Graham, DY; Husni, ME; Iorga, D; Krum, H; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wisniewski, LM; Yeomans, ND | 1 |
| Weintraub, WS | 1 |
| Radhakrishnan, J; Radhakrishnan, R; Yellepeddi, VK | 1 |
| Bao, W; Berger, MF; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND | 1 |
| Chang, CH; Dong, YH; Hwang, JS; Toh, S; Wu, LC | 1 |
| Bao, W; Borer, J; Graham, DY; Husni, EM; Libby, P; Lincoff, MA; Lüscher, T; Nissen, SE; Walker, C; Wang, Q; Wisniewski, LM; Wolski, K; Yeomans, ND | 1 |
| Bao, W; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Nissen, SE; Solomon, DH; Stevens, T; Vargo, J; Walker, C; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND | 1 |
| Antman, EM | 1 |
| Laine, L | 1 |
| Graham, DY; Yeomans, ND | 1 |
| Madka, V; Mohammed, A; Rao, CV; Yarla, NS | 1 |
| Buschiazzo, HO; Cañás, M; Dorati, CM; Mordujovich-Buschiazzo, P; Prozzi, GR; Urtasun, MA | 1 |
| Bordy, R; Demougeot, C; Prati, C; Totoson, P; Verhoeven, F; Wendling, D | 1 |
| Husni, ME; Nissen, S; Paynter, N; Shao, M; Solomon, DH; Wolski, K | 1 |
| Abdelhamid, AA; Al-Sanea, MM; Gomaa, HAM; Mohamed, MFA; Moustafa, AH; Youssif, BGM | 1 |
| Nissen, SE; Reed, GW | 1 |
| Breitner, JCS; Labonté, A; Meyer, PF; Poirier, J; Rosa-Neto, P | 1 |
| Naserzadeh, P; Neshat, MR; Pourahmad, J; Salimi, A | 1 |
| Kang, CN; Kim, HJ; Kim, JH; Lee, S; Lee, WS; Moon, SH; Park, MS; Shin, SJ | 1 |
| Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C | 1 |
| Brown, MT; Carrino, JA; Fountaine, RJ; Guermazi, A; Hickman, A; Hochberg, MC; Nakajo, S; Pixton, G; Schnitzer, TJ; Verburg, KM; Viktrup, L; Walsh, DA; West, CR; White, A | 1 |
| Bao, W; Davey, DA; Husni, E; Libby, P; Lüscher, TF; Nissen, SE; Obeid, S; Ruschitzka, F; Walker, C; Wang, Q; Wisniewski, LM; Wolski, KE; Xia, F | 1 |
| Ding, X; Li, X; Lu, N; Wang, Y; Wu, Z | 1 |
| Barakat, A; Diaz-delCastillo, M; Heegaard, AM; Rice, ASC; Sena, ES; Soliman, N; Vollert, J; Zhang, XY | 1 |
| Hjemdahl, P; Stiller, CO | 1 |
| Asparago, G; Cuozzo, F; Maffulli, N; Migliorini, F; Oliva, F | 1 |
| Kang, M; Kim, B; Kim, MG; Moon, SJ; Shin, N | 1 |
| Gorenflo, M; Saur, P; van den Anker, JN; van Dyk, M; Welzel, T; Ziesenitz, VC | 1 |
| Andrews, GP; Jacobs, E; Jones, DS; Pietsch, VL; Qian, K; Richter, M; Tian, Y | 1 |
| Abdelhady, SA; Ali, MA; El-Mas, MM; Elblehi, SS; Kandil, LS; Yacout, DM | 1 |
| Abdelhady, SA; Ali, MA; El-Mas, MM; Essawy, MM; Kandil, LS; Yacout, DM | 1 |
27 review(s) available for naproxen and celecoxib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Controlled Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etodolac; Gene Expression; Humans; Ibuprofen; Indomethacin; Isoenzymes; Meloxicam; Membrane Proteins; Naproxen; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Thiazines; Thiazoles | 1999 |
Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience.
Topics: Analgesics; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials, Phase III as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Humans; Isoenzymes; Joints; Membrane Proteins; Naproxen; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Treatment Outcome | 2000 |
Celecoxib clinical profile.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; In Vitro Techniques; Isoenzymes; Kidney Diseases; Membrane Proteins; Middle Aged; Naproxen; Osteoarthritis; Pain; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2000 |
NSAIDs and Alzheimer's disease: how far to generalise from trials?
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides | 2003 |
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; Diclofenac; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Pain; Pain, Postoperative; Placebos; Pyrazoles; Sulfonamides; Sulfones | 2003 |
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cost-Benefit Analysis; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Lactones; Lansoprazole; Naproxen; Omeprazole; Proton Pump Inhibitors; Pyrazoles; Rheumatology; Sulfonamides; Sulfones | 2005 |
[Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Humans; Kidney Diseases; Naproxen; Pyrazoles; Risk Assessment; Sulfonamides; Thromboembolism | 2005 |
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Topics: Cardiovascular Diseases; Celecoxib; Cell Proliferation; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Heart Failure; Hemostasis; Humans; Hypertension; Lactones; Naproxen; Natriuretic Peptide, Brain; Peptide Fragments; Pyrazoles; Sulfonamides; Sulfones | 2006 |
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Lactones; Naproxen; Pyrazoles; Risk; Sulfonamides; Sulfones | 2006 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
Nonsteroidal anti-inflammatory drugs: cyclooxygenase 2 inhibitors.
Topics: Adolescent; Aspirin; Celecoxib; Child; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Interactions; Etoricoxib; Fever; Humans; Hypersensitivity, Immediate; Inflammation; Leukotrienes; Meloxicam; Naproxen; Pain; Prostaglandins; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Thiazines; Thiazoles; Treatment Outcome | 2006 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2007 |
Pharmacological treatment of heterotopic ossification following hip and acetabular surgery.
Topics: Acetabulum; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Celecoxib; Diclofenac; Humans; Indomethacin; Naproxen; Ossification, Heterotopic; Postoperative Complications; Pyrazoles; Sulfonamides | 2008 |
Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
Topics: Age Factors; Aged; Amitriptyline; Analgesics; Cardiovascular Diseases; Celecoxib; Chronic Disease; Clinical Trials as Topic; Cost-Benefit Analysis; Duloxetine Hydrochloride; gamma-Aminobutyric Acid; Gastrointestinal Diseases; Humans; Hydromorphone; Low Back Pain; Markov Chains; Middle Aged; Models, Economic; Naproxen; Ontario; Osteoarthritis; Outcome Assessment, Health Care; Oxycodone; Pregabalin; Pyrazoles; Quality-Adjusted Life Years; Quebec; Sulfonamides; Thiophenes | 2013 |
Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Naproxen; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2014 |
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
Topics: Acetaminophen; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Hyaluronic Acid; Ibuprofen; Injections, Intra-Articular; Naproxen; Osteoarthritis, Knee; Pain; Pyrazoles; Sulfonamides; Treatment Outcome; Viscosupplements | 2015 |
Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cerebral Hemorrhage; Diclofenac; Humans; Ibuprofen; Incidence; Indomethacin; Lactones; Meloxicam; Naproxen; Observational Studies as Topic; Odds Ratio; Piroxicam; Proportional Hazards Models; Stroke; Sulfones; Thiazines; Thiazoles | 2016 |
Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bayes Theorem; Celecoxib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etoricoxib; Female; Humans; Male; Middle Aged; Naproxen; Osteoarthritis; Outcome Assessment, Health Care; Proportional Hazards Models; Pyridines; Randomized Controlled Trials as Topic; Sulfones; Treatment Outcome | 2016 |
Celecoxib for osteoarthritis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Female; Humans; Male; Middle Aged; Naproxen; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain Measurement; Placebos; Quality of Life; Randomized Controlled Trials as Topic | 2017 |
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Arthritis, Rheumatoid; Aspirin; Celecoxib; Child; Child, Preschool; Chronic Disease; Chronic Pain; Fenoprofen; Humans; Ibuprofen; Lactones; Meloxicam; Methoxsalen; Naproxen; Randomized Controlled Trials as Topic; Sulfones; Thiazines; Thiazoles | 2017 |
Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Celecoxib; Chemoprevention; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Naproxen; Neoplasm Recurrence, Local | 2018 |
[Cardiovascular risk of non-steroidal anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Drug Interactions; Humans; Ibuprofen; Naproxen; Risk Factors | 2018 |
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Dementia; Hemorrhage; Humans; Incidence; Lactones; Middle Aged; Myocardial Infarction; Naproxen; Randomized Controlled Trials as Topic; Stroke; Sulfones | 2020 |
Systematic review and meta-analysis of studies in which burrowing behaviour was assessed in rodent models of disease-associated persistent pain.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; Disease Models, Animal; Gabapentin; Ibuprofen; Male; Naproxen; Pain; Rats; Rodentia | 2022 |
Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Fibrinolytic Agents; Humans; Ibuprofen; Lactones; Naproxen; Prostaglandins; Prostaglandins I; Sulfones; Thromboxanes | 2022 |
Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.
Topics: Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Child; Chronic Disease; Diclofenac; Flurbiprofen; Humans; Ibuprofen; Infant; Ketoprofen; Ketorolac; Meloxicam; Naproxen; Niflumic Acid; Pain | 2022 |
67 trial(s) available for naproxen and celecoxib
| Article | Year |
|---|---|
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Endoscopy; Female; Humans; Knee Joint; Male; Middle Aged; Naproxen; Osteoarthritis; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazoles; Safety; Severity of Illness Index; Stomach Ulcer; Sulfonamides; Thromboxane B2; Treatment Outcome | 1998 |
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.
Topics: Adult; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Humans; Isoenzymes; Kidney; Lithium; Male; Membrane Proteins; Naproxen; Potassium; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Reference Values; Sodium; Sulfonamides; Volunteers | 1999 |
Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Administration Schedule; Humans; Incidence; Isoenzymes; Membrane Proteins; Middle Aged; Naproxen; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Treatment Outcome | 1999 |
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Duodenum; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; Humans; Intestinal Mucosa; Isoenzymes; Male; Membrane Proteins; Middle Aged; Naproxen; Peptic Ulcer; Prospective Studies; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 1999 |
Effects of celecoxib and naproxen on renal function in the elderly.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cross-Over Studies; Cyclooxygenase Inhibitors; Female; Humans; Kidney; Kidney Function Tests; Male; Naproxen; Pyrazoles; Single-Blind Method; Sulfonamides | 2000 |
Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Digestive System; Double-Blind Method; Dyspepsia; Female; Humans; Isoenzymes; Male; Membrane Proteins; Middle Aged; Naproxen; Nausea; Osteoarthritis; Prospective Studies; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Time Factors; Treatment Outcome | 2000 |
Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib.
Topics: Aged; Aged, 80 and over; Aging; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Health Status; Humans; Male; Naproxen; Osteoarthritis; Prospective Studies; Pyrazoles; Quality of Life; Sulfonamides | 2001 |
Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Endoscopy, Gastrointestinal; Female; Humans; Incidence; Male; Middle Aged; Naproxen; Peptic Ulcer; Pyrazoles; Risk Factors; Sulfonamides | 2001 |
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
Topics: Aged; Aged, 80 and over; Blood Pressure; Body Weight; Celecoxib; Creatinine; Cyclooxygenase Inhibitors; Diet; Double-Blind Method; Electrolytes; Female; Humans; Kidney; Lactones; Male; Middle Aged; Naproxen; Potassium; Pyrazoles; Sodium; Sodium Chloride, Dietary; Sulfonamides; Sulfones | 2002 |
Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Canada; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Health Status; Humans; Male; Middle Aged; Naproxen; Prospective Studies; Pyrazoles; Quality of Life; Sulfonamides; Surveys and Questionnaires; Treatment Outcome; United States | 2000 |
Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Celecoxib; Computer Graphics; Cross-Over Studies; Cyclooxygenase Inhibitors; Cysteine; Double-Blind Method; Drug Eruptions; Female; Humans; Lactones; Leukotriene E4; Leukotrienes; Male; Middle Aged; Multivariate Analysis; Naproxen; Prospective Studies; Pyrazoles; Serine Endopeptidases; Skin; Sulfonamides; Sulfones; Treatment Outcome; Tryptases; Urticaria | 2003 |
A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury.
Topics: Adolescent; Adult; Aged; Celecoxib; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; Humans; Ibuprofen; Intestinal Mucosa; Male; Maximum Tolerated Dose; Middle Aged; Naproxen; Nonprescription Drugs; Probability; Pyrazoles; Reference Values; Risk Assessment; Sensitivity and Specificity; Sulfonamides | 2004 |
Efficacy of celecoxib, a COX-2-specific inhibitor, and naproxen in the management of acute ankle sprain: results of a double-blind, randomized controlled trial.
Topics: Acute Disease; Adult; Ankle Injuries; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Male; Naproxen; Pain Measurement; Pyrazoles; Recovery of Function; Sprains and Strains; Sulfonamides; Treatment Outcome | 2004 |
Celecoxib effectively treats patients with acute shoulder tendinitis/bursitis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Bursitis; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Naproxen; Palliative Care; Patient Satisfaction; Pyrazoles; Shoulder Joint; Sulfonamides; Tendinopathy; Treatment Outcome | 2004 |
Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen.
Topics: Adult; Celecoxib; Chronic Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Facial Pain; Female; Humans; Isoenzymes; Male; Membrane Proteins; Middle Aged; Naproxen; Placebos; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quality of Life; Range of Motion, Articular; Sulfonamides; Temporomandibular Joint Disorders; Treatment Outcome | 2004 |
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Blood Pressure Determination; Celecoxib; Cyclooxygenase Inhibitors; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Hypertension; Lactones; Male; Middle Aged; Naproxen; Osteoarthritis; Probability; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo.
Topics: Adolescent; Adult; Aged; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Humans; Intestinal Mucosa; Intestine, Small; Male; Middle Aged; Naproxen; Omeprazole; Probability; Prospective Studies; Pyrazoles; Reference Values; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Sulfonamides; Video Recording | 2005 |
Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.
Topics: Ascites; Celecoxib; Dinoprostone; Double-Blind Method; Female; Furosemide; Glomerular Filtration Rate; Humans; Kidney; Liver Cirrhosis; Male; Middle Aged; Naproxen; Platelet Aggregation; Pyrazoles; Renin; Sulfonamides | 2005 |
Re: Efficacy of celecoxib, a COX-2-specific inhibitor, and naproxen in the management of acute ankle sprain: results of a double-blind, randomized controlled trial.
Topics: Acute Disease; Administration, Oral; Ankle Injuries; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injury Severity Score; Male; Naproxen; Pain Measurement; Probability; Pyrazoles; Sprains and Strains; Sulfonamides; Treatment Outcome | 2005 |
What are the effects of cyclooxygenase-2-specific inhibitors on the small bowel?
Topics: Adult; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Naproxen; Omeprazole; Prospective Studies; Pyrazoles; Sulfonamides | 2005 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Male; Middle Aged; Naproxen; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Prospective Studies; Proton Pump Inhibitors; Pyrazoles; Recurrence; Risk Factors; Sulfonamides; Treatment Outcome | 2005 |
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Naproxen; Osteoarthritis; Pain; Pyrazoles; Severity of Illness Index; Sulfonamides | 2006 |
The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Administration Schedule; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Humans; Male; Middle Aged; Naproxen; Prospective Studies; Pyrazoles; Stomach Ulcer; Sulfonamides; Treatment Outcome | 2006 |
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.
Topics: Adult; Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cyclooxygenase Inhibitors; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Naproxen; Nootropic Agents; Patient Selection; Pyrazoles; Selection Bias; Sulfonamides; Treatment Failure; Treatment Outcome | 2007 |
Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or coadministered with celecoxib or naproxen: a randomized, 1-week trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Humans; Male; Middle Aged; Naproxen; Pyrazoles; Random Allocation; Stomach Ulcer; Sulfonamides | 2008 |
Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers.
Topics: Adult; Antigens, Neoplasm; Blood Platelets; Celecoxib; Cell Adhesion; Cyclic AMP; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Fibrinogen; Humans; Lactones; Leukocytes; Male; Naproxen; P-Selectin; Phospholipases A; Platelet Activation; Platelet Aggregation; Platelet Membrane Glycoprotein IIb; Prostaglandins; Pyrazoles; Reference Values; Sulfonamides; Sulfones; Thrombin; Thrombomodulin; Thromboxanes; Time Factors | 2007 |
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Confidence Intervals; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Lansoprazole; Male; Middle Aged; Naproxen; Osteoarthritis; Proton Pump Inhibitors; Pyrazoles; Retrospective Studies; Risk Factors; Stomach Ulcer; Sulfonamides; United States | 2007 |
Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.
Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Body Weight; Celecoxib; Constipation; Creatinine; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Electrolytes; Etoricoxib; Female; Headache; Humans; Male; Middle Aged; Naproxen; Potassium; Prostaglandins; Pyrazoles; Pyridines; Sodium; Sulfonamides; Sulfones; Thromboxane B2 | 2007 |
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cognition; Cognition Disorders; Double-Blind Method; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Naproxen; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome | 2008 |
A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Celecoxib; Child; Child, Preschool; Female; Humans; Infant; Male; Naproxen; Prospective Studies; Pyrazoles; Sulfonamides; Treatment Outcome | 2009 |
A randomized, placebo-controlled study of the effects of naproxen, aspirin, celecoxib or clopidogrel on gastroduodenal mucosal healing.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clopidogrel; Drug Administration Schedule; Female; Gastric Mucosa; Humans; Male; Middle Aged; Naproxen; Peptic Ulcer; Pilot Projects; Pyrazoles; Sulfonamides; Ticlopidine; Young Adult | 2009 |
The impact of selective and non-selective non-steroid anti-inflammatory drugs on secondary hemostasis in healthy volunteers.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Factor XII; Hemostasis; Humans; Male; Naproxen; Pyrazoles; Risk Factors; Sulfonamides | 2009 |
Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cognition Disorders; Encephalitis; Female; Humans; Male; Naproxen; Neuropsychological Tests; Outcome Assessment, Health Care; Patient Selection; Placebos; Pyrazoles; Research Design; Sulfonamides; Time; Treatment Outcome | 2009 |
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Ibuprofen; Middle Aged; Naproxen; Prospective Studies; Pyrazoles; Sulfonamides; Treatment Outcome | 2009 |
Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Double-Blind Method; Dysmenorrhea; Female; Follow-Up Studies; Humans; Naproxen; Pain Measurement; Pyrazoles; Sulfonamides; Young Adult | 2009 |
Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; C-Reactive Protein; Celecoxib; Cyclooxygenase 2 Inhibitors; Epidemiologic Methods; Female; Humans; Ketoprofen; Male; Middle Aged; Naproxen; Pyrazoles; Spondylitis, Ankylosing; Sulfonamides; Treatment Outcome | 2010 |
Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Drug Therapy, Combination; F2-Isoprostanes; Female; Humans; Male; Naproxen; Pyrazoles; Sulfonamides; Thromboxane B2; Treatment Outcome | 2010 |
Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials.
Topics: Celecoxib; Double-Blind Method; Drug Combinations; Esomeprazole; Humans; Naproxen; Osteoarthritis, Knee; Placebos; Pyrazoles; Sulfonamides; Treatment Outcome | 2011 |
Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cognition; Female; Humans; Longitudinal Studies; Male; Middle Aged; Naproxen; Pyrazoles; Sulfonamides | 2012 |
Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Depression; Female; Humans; Longitudinal Studies; Male; Naproxen; Pyrazoles; Sulfonamides; Treatment Outcome | 2012 |
Extended results of the Alzheimer's disease anti-inflammatory prevention trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Confidence Intervals; Double-Blind Method; Female; Humans; Longitudinal Studies; Male; Naproxen; Neuropsychological Tests; Peptide Fragments; Proportional Hazards Models; Psychiatric Status Rating Scales; Pyrazoles; Sulfonamides; tau Proteins | 2011 |
A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Combinations; Dyspepsia; Esomeprazole; Female; Gastrointestinal Tract; Heartburn; Humans; Male; Middle Aged; Naproxen; Osteoarthritis, Knee; Pyrazoles; Sulfonamides; Tablets, Enteric-Coated; Treatment Outcome | 2011 |
Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: a randomized, double-blind, double-dummy trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naproxen; Osteoarthritis, Knee; Pyrazoles; Sulfonamides; Treatment Outcome | 2012 |
Response to nonsteroidal anti-inflammatory drugs in African Americans with osteoarthritis of the knee.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Black or African American; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Naproxen; Osteoarthritis, Knee; Pain Measurement; Placebo Effect; Placebos; Pyrazoles; Sulfonamides; Treatment Outcome | 2012 |
Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Celecoxib; Cognition Disorders; Double-Blind Method; Female; Humans; Inflammation; Longitudinal Studies; Male; Naproxen; Physical Examination; Pyrazoles; Sulfonamides; Treatment Outcome | 2013 |
Screening by telephone in the Alzheimer's disease anti-inflammatory prevention trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Celecoxib; Cognition Disorders; Female; Geriatric Assessment; Humans; Male; Mass Screening; Naproxen; Neuropsychological Tests; Pyrazoles; Sulfonamides; Telephone | 2013 |
Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: conceptual framework and example.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Biomarkers; Celecoxib; Computer Simulation; Cyclooxygenase 2 Inhibitors; Female; Humans; Longitudinal Studies; Male; Models, Statistical; Naproxen; Pyrazoles; Sulfonamides | 2014 |
NSAIDs are associated with lower depression scores in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Depression; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibuprofen; Logistic Models; Male; Middle Aged; Multivariate Analysis; Naproxen; Osteoarthritis; Psychological Tests; Pyrazoles; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2013 |
Clinical use of cyclooxygenase inhibitors impairs vitamin B-6 metabolism.
Topics: Animals; Arthritis, Rheumatoid; Celecoxib; Cricetinae; Cross-Sectional Studies; Cyclooxygenase Inhibitors; Drug Monitoring; Female; Humans; Kidney; Liver; Male; Mesocricetus; Mice; Mice, Inbred C57BL; Middle Aged; Naproxen; Pyrazoles; Pyridoxal Phosphate; Sulfonamides; Vitamin B 6; Vitamin B 6 Deficiency | 2013 |
Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Arthralgia; Arthroplasty, Replacement; Celecoxib; Double-Blind Method; Drug Therapy, Combination; Edema; Female; Humans; Hypesthesia; Male; Middle Aged; Naproxen; Osteoarthritis, Hip; Osteoarthritis, Knee; Paresthesia; Pyrazoles; Sulfonamides; Treatment Outcome | 2015 |
Assessment of common nonsteroidal anti-inflammatory medications by whole blood aggregometry: a clinical evaluation for the perioperative setting.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Loss, Surgical; Celecoxib; Cyclooxygenase Inhibitors; Female; Healthy Volunteers; Humans; Ibuprofen; Male; Meloxicam; Middle Aged; Naproxen; Perioperative Care; Platelet Aggregation; Pyrazoles; Sulfonamides; Thiazines; Thiazoles; Young Adult | 2014 |
Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Celecoxib; Cognition; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Naproxen; Neuropsychological Tests; Nootropic Agents; Sensitivity and Specificity; Treatment Outcome | 2015 |
Efficacy and safety of nonsteroidal anti-inflammatory drugs in Asian patients with knee osteoarthritis: summary of a randomized, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Asian; Celecoxib; Disability Evaluation; Double-Blind Method; Female; Humans; Knee Joint; Male; Middle Aged; Naproxen; Osteoarthritis, Knee; Pain Measurement; Patient Satisfaction; Recovery of Function; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2016 |
Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Humans; Male; Middle Aged; Naproxen; Osteoarthritis, Knee; Pain; Pain Measurement; Proton Pump Inhibitors | 2015 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Intention to Treat Analysis; Kidney Diseases; Male; Middle Aged; Naproxen; Risk | 2016 |
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ibuprofen; Male; Naproxen; Osteoarthritis; Proton Pump Inhibitors; Survival Analysis; United States; United States Food and Drug Administration | 2017 |
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Middle Aged; Naproxen; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Recurrence; Secondary Prevention | 2017 |
The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis | 2017 |
Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement)
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecoxib; Coronary Artery Disease; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Humans; Hypertension; Ibuprofen; Male; Naproxen; Osteoarthritis; Prospective Studies | 2017 |
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Kidney Diseases; Male; Middle Aged; Naproxen; Osteoarthritis; Risk Factors; Treatment Outcome | 2018 |
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspirin; Celecoxib; Double-Blind Method; Drug Therapy, Combination; Esomeprazole; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis; Treatment Outcome | 2018 |
Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis; Reproducibility of Results; Risk Assessment; Risk Factors | 2019 |
No apparent effect of naproxen on CSF markers of innate immune activation.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Celecoxib; Cytokines; Female; Humans; Interferon alpha-2; Interleukin 1 Receptor Antagonist Protein; Male; Middle Aged; Naproxen | 2019 |
A comparative study of the efficacy of NAXOZOL compared to celecoxib in patients with osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Double-Blind Method; Esomeprazole; Female; Gastrointestinal Diseases; Humans; Male; Naproxen; Osteoarthritis; Pain; Prospective Studies; Surveys and Questionnaires | 2020 |
Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Blocking; Antibodies, Monoclonal, Humanized; Celecoxib; Diclofenac; Disease Progression; Double-Blind Method; Female; Fractures, Bone; Fractures, Spontaneous; Humans; Injections, Subcutaneous; Intra-Articular Fractures; Male; Middle Aged; Naproxen; Nerve Growth Factor; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteonecrosis; Treatment Outcome | 2021 |
Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Humans; Ibuprofen; Naproxen; Prospective Studies | 2022 |
Pharmacokinetic Interactions Between Tegoprazan and Naproxen, Aceclofenac, and Celecoxib in Healthy Korean Male Subjects.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Benzene Derivatives; Celecoxib; Cross-Over Studies; Diclofenac; Humans; Imidazoles; Male; Naproxen; Republic of Korea; Tablets | 2022 |
107 other study(ies) available for naproxen and celecoxib
| Article | Year |
|---|---|
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Carrageenan; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Hyperalgesia; Isoenzymes; Magnetic Resonance Spectroscopy; Male; Membrane Proteins; Molecular Structure; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfonamides | 1997 |
Synthesis and biological evaluation of 3,4-diaryloxazolones: A new class of orally active cyclooxygenase-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cyclooxygenase Inhibitors; Fever; Humans; Magnetic Resonance Spectroscopy; Male; Oxazoles; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Wistar; Structure-Activity Relationship | 2000 |
Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthritis, Rheumatoid; Biological Availability; Cytochrome P-450 Enzyme Inhibitors; Databases, Factual; Edema; Humans; Hydroxyquinolines; In Vitro Techniques; Leukocyte Rolling; Male; P-Selectin; Quinolines; Rats; Rats, Sprague-Dawley; Salicylates; Structure-Activity Relationship | 2007 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: synthesis of artificial substrate, homology modelling and initial screening.
Topics: Amino Acid Sequence; Ascomycota; Benzopyrans; Enzyme Inhibitors; Fungal Proteins; Melanins; Models, Molecular; Molecular Sequence Data; Oxidoreductases Acting on CH-CH Group Donors; Recombinant Proteins; Structural Homology, Protein; Substrate Specificity | 2008 |
Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Benzoates; Biological Availability; Bronchoconstriction; Calorimetry; Carrageenan; Cell Line; Cyclooxygenase 2 Inhibitors; Edema; Group IV Phospholipases A2; Humans; In Vitro Techniques; Isoenzymes; Male; Mice; Protein Binding; Rats; Rats, Sprague-Dawley; Sheep; Structure-Activity Relationship; Sulfonamides | 2008 |
Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.
Topics: Animals; Enzyme Inhibitors; Group IV Phospholipases A2; Hydrophobic and Hydrophilic Interactions; Rats; Structure-Activity Relationship; Sulfides; Sulfonamides | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.
Topics: Animals; Anti-Inflammatory Agents; Catalytic Domain; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Design; Edema; Female; Lipoxygenase; Lipoxygenase Inhibitors; Male; Mice; Models, Molecular; Structure-Activity Relationship; Thiazolidines | 2012 |
Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker.
Topics: Acridines; Acridones; Biomarkers, Tumor; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Fluorescent Dyes; Humans; Ibuprofen; Microscopy, Confocal; Protein Binding; Pyrazoles; Rhodamines; Structure-Activity Relationship; Sulfonamides | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Lipid Peroxidation and Cyclooxygenase Enzyme Inhibitory Compounds from Prangos haussknechtii.
Topics: Anti-Inflammatory Agents; Antioxidants; Coumarins; Cyclooxygenase Inhibitors; Lipid Peroxidation; Molecular Structure; Plant Extracts; Tetrazoles; Tetrazolium Salts; Thiazoles | 2017 |
Synthesis and biological properties of aryl methyl sulfones.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Carrageenan; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Edema; Humans; Male; Mice; Models, Molecular; Molecular Structure; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Structure-Activity Relationship; Sulfones; Thermodynamics | 2018 |
Kinetic basis for selective inhibition of cyclo-oxygenases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding, Competitive; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Ibuprofen; Indomethacin; Inhibitory Concentration 50; Isoenzymes; Kinetics; Male; Membrane Proteins; Mice; Naproxen; Oxygen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sheep; Structure-Activity Relationship; Sulfonamides; Tetramethylphenylenediamine; Thermodynamics | 1999 |
Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Collagen; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Exudates and Transudates; Gastric Mucosa; Inflammation; Isoenzymes; Male; Membrane Proteins; Naproxen; Nitrates; Nitric Oxide Donors; Nitrites; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Thromboxanes; Wound Healing | 2000 |
Celecoxib for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Naproxen; Peptic Ulcer; Pyrazoles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sulfonamides; Treatment Outcome | 2000 |
Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chromatography, High Pressure Liquid; Confidence Intervals; Cyclooxygenase Inhibitors; Delayed-Action Preparations; Female; Gastric Mucosa; Humans; Indomethacin; Intestinal Mucosa; Lactulose; Male; Mannitol; Meloxicam; Middle Aged; Naproxen; Permeability; Pyrazoles; Statistics, Nonparametric; Sucrose; Sulfonamides; Thiazines; Thiazoles | 2001 |
Nonsteroidal anti-inflammatory drugs for perioperative pain control.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Etodolac; Humans; Ibuprofen; Indomethacin; Ketorolac; Lactones; Nabumetone; Naproxen; Pain, Postoperative; Piroxicam; Pyrazoles; Sulfonamides; Sulfones; Time Factors | 2001 |
[Renal tolerance of selective inhibitors of cyclooxygenase type 2].
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Diclofenac; Humans; Kidney; Kidney Diseases; Lactones; Naproxen; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Rats; Risk Factors; Sulfonamides; Sulfones; Water-Electrolyte Imbalance | 2001 |
Characterization, quantification, and bioactivities of anthocyanins in Cornus species.
Topics: Anthocyanins; Antioxidants; Celecoxib; Chromatography, High Pressure Liquid; Cornus; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fruit; Ibuprofen; Isoenzymes; Lactones; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones | 2002 |
Bioactivity of alkamides isolated from Echinacea purpurea (L.) Moench.
Topics: Aedes; Amides; Animals; Anti-Inflammatory Agents; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Echinacea; Ibuprofen; Isoenzymes; Lactones; Lethal Dose 50; Naproxen; Phytotherapy; Plant Extracts; Plant Roots; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones | 2002 |
NSAIDS for prevention? Protecting the brain while killing pain?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxib; Cells, Cultured; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Naproxen; Neurons; Peptide Fragments; Pyrazoles; Sulfonamides | 2002 |
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Coronary Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Ibuprofen; Isoenzymes; Lactones; Male; Medicaid; Membrane Proteins; Middle Aged; Naproxen; Product Surveillance, Postmarketing; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Regression Analysis; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones; Tennessee | 2002 |
Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Lactones; Male; Myocardial Infarction; Naproxen; Ontario; Proportional Hazards Models; Pyrazoles; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones | 2003 |
Pharmacological characterisation of a rat model of incisional pain.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Evaluation, Preclinical; Etoricoxib; Foot; Gabapentin; gamma-Aminobutyric Acid; Hindlimb; Hyperalgesia; Indomethacin; Male; Morphine; Muscle, Skeletal; Naproxen; Nociceptors; Pain Threshold; Pain, Postoperative; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sulfonamides; Sulfones; Time Factors; Weight-Bearing | 2004 |
Persistence with COX-2 inhibitors in managed care: an analysis of claims data.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Utilization Review; Female; Health Care Costs; Humans; Ibuprofen; Insurance Claim Review; Isoenzymes; Lactones; Male; Managed Care Programs; Membrane Proteins; Middle Aged; Naproxen; Patient Compliance; Proportional Hazards Models; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Regression Analysis; Sulfonamides; Sulfones; United States | 2003 |
Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.
Topics: Abdominal Pain; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Dyspepsia; Female; Humans; Ibuprofen; Incidence; Insurance Claim Reporting; Male; Middle Aged; Naproxen; Nausea; Outpatients; Poisson Distribution; Proportional Hazards Models; Pyrazoles; Risk Factors; Sulfonamides; United States; Vomiting | 2003 |
Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Community Health Services; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Fibromyalgia; Follow-Up Studies; Humans; Ibuprofen; Isoenzymes; Lactones; Longitudinal Studies; Male; Membrane Proteins; Middle Aged; Naproxen; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Surveys and Questionnaires | 2004 |
Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Nonprescription Drugs; Pyrazoles; Sulfonamides | 2004 |
Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Eicosanoids; Freund's Adjuvant; Gastric Mucosa; Isoenzymes; Lipoxins; Male; Membrane Proteins; Naproxen; Nitric Oxide; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Rats; Rats, Inbred Lew; Reverse Transcriptase Polymerase Chain Reaction; Stomach Ulcer; Sulfonamides | 2004 |
Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit Analysis; Female; Humans; Hyaluronic Acid; Middle Aged; Naproxen; Osteoarthritis, Knee; Pyrazoles; Sensitivity and Specificity; Sulfonamides; Taiwan | 2004 |
Multiple comparisons with a control in families with both one-sided and two-sided hypotheses.
Topics: Aged; Anti-Inflammatory Agents; Celecoxib; Clinical Trials as Topic; Computer Simulation; Data Interpretation, Statistical; Humans; Lactones; Naproxen; Pyrazoles; Research Design; Sodium; Sulfonamides; Sulfones | 2004 |
[Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Endoscopy, Digestive System; Gastric Mucosa; Humans; Intestinal Mucosa; Isoenzymes; Membrane Proteins; Middle Aged; Naproxen; Omeprazole; Osteoarthritis; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides | 2004 |
Coxibs and cardiovascular disease.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Epoprostenol; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk; Sulfonamides; Sulfones; Thromboxane A2; United States; United States Food and Drug Administration | 2004 |
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.
Topics: Animals; Antioxidants; Celecoxib; Cholesterol, LDL; Chromans; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Isoprostanes; Isoxazoles; Lactones; Meloxicam; Naproxen; Oxidation-Reduction; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles | 2004 |
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Case-Control Studies; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Risk Factors; Sulfonamides; Sulfones | 2005 |
Safety of short-term administration of celecoxib in decompensated cirrhosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Kidney Diseases; Liver Cirrhosis; Naproxen; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Drug testing. Massive trial of Celebrex seeks to settle safety concerns.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Interactions; Heart Diseases; Humans; Ibuprofen; Membrane Proteins; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Sulfonamides | 2005 |
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2 | 2006 |
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug-Related Side Effects and Adverse Reactions; Humans; Isoxazoles; Lactones; Marketing of Health Services; Naproxen; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2005 |
Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cross-Sectional Studies; Diclofenac; Female; Humans; Indomethacin; Male; Middle Aged; Naproxen; Pain; Pain Measurement; Patient Satisfaction; Pyrazoles; Retreatment; Spondylitis, Ankylosing; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2006 |
Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro.
Topics: Animals; Antirheumatic Agents; Benzodiazepines; Benzodiazepinones; Celecoxib; Cell Line; Cell Proliferation; Cell Survival; Diclofenac; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Inhibitory Concentration 50; Methotrexate; Naproxen; Pyrazoles; Quinoxalines; Sulfasalazine; Sulfonamides; Synovial Membrane | 2006 |
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Etodolac; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Naproxen; Pyrazoles; Sulfonamides; Sulfones; Time Factors; United States; Veterans | 2006 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Computer Simulation; Coronary Disease; Cyclooxygenase Inhibitors; Diclofenac; Female; Heart Failure; Humans; Ibuprofen; Male; Middle Aged; Models, Statistical; Naproxen; Peptic Ulcer; Population Surveillance; Pyrazoles; Risk Assessment; Risk Factors; Stroke; Sulfonamides; United States | 2007 |
Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Lactones; Male; Multivariate Analysis; Myocardial Infarction; Naproxen; Pyrazoles; Rheumatic Diseases; Risk Assessment; Risk Factors; Sulfonamides; Sulfones | 2006 |
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hospitalization; Humans; Lactones; Male; Myocardial Infarction; Naproxen; Pyrazoles; Quebec; Retrospective Studies; Risk Assessment; Sulfonamides; Sulfones | 2007 |
12 things you should know about pain relievers. A dozen take-home messages about the pills that take the hurt away.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Celecoxib; Humans; Naproxen; Pharmacogenetics; Pyrazoles; Sulfonamides | 2007 |
An economic model of long-term use of celecoxib in patients with osteoarthritis.
Topics: Age Factors; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit Analysis; Diclofenac; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Long-Term Care; Male; Maximum Tolerated Dose; Middle Aged; Models, Economic; Naproxen; Osteoarthritis; Probability; Pyrazoles; Quality-Adjusted Life Years; Risk Factors; Sensitivity and Specificity; Severity of Illness Index; Sulfonamides | 2007 |
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Celecoxib; Cytochrome P-450 CYP2C9; Diclofenac; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Odds Ratio; Peptic Ulcer; Peptic Ulcer Hemorrhage; Piroxicam; Polymorphism, Single Nucleotide; Pyrazoles; Risk Assessment; Risk Factors; Sulfonamides | 2007 |
Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
Topics: Adverse Drug Reaction Reporting Systems; Algorithms; Celecoxib; Competitive Medical Plans; Health Maintenance Organizations; Humans; Insurance Claim Review; Lactones; Medical Records Systems, Computerized; Myocardial Infarction; Naproxen; Population Surveillance; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Retrospective Studies; Rhabdomyolysis; Sulfonamides; Sulfones; Time Factors; Treatment Outcome; United States | 2007 |
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; Follow-Up Studies; Humans; Isoxazoles; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Osteoarthritis; Proportional Hazards Models; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; United States | 2008 |
Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Caco-2 Cells; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Naproxen; Neoplasm Proteins; Pyrazoles; Reproducibility of Results; RNA, Messenger; Sulfonamides; Time Factors | 2008 |
Anti-inflammatory drugs fall short in Alzheimer's disease.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cognition; Humans; Naproxen; Pyrazoles; Sulfonamides | 2008 |
The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Drug Utilization Review; Drugs, Generic; Etodolac; Humans; Incidence; Lactones; Male; Medical Records; Middle Aged; Myocardial Infarction; Naproxen; Prevalence; Prognosis; Pyrazoles; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Texas; Veterans | 2008 |
Hepatic stellate cells promote hepatocyte engraftment in rat liver after prostaglandin-endoperoxide synthase inhibition.
Topics: Analysis of Variance; Animals; Blotting, Western; Celecoxib; Cell Survival; Cells, Cultured; Disease Models, Animal; Female; Graft Survival; Hepatic Stellate Cells; Hepatocytes; Immunohistochemistry; Kupffer Cells; Male; Naproxen; Phagocytosis; Probability; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Random Allocation; Rats; Rats, Inbred F344; RNA, Messenger; Signal Transduction; Sulfonamides | 2009 |
Can treatment with nonsteroidal anti-inflammatory drugs protect from dementia?
Topics: Adult; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2009 |
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Coronary Artery Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Follow-Up Studies; Hospitalization; Humans; Ibuprofen; Incidence; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Outpatients; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; Tennessee | 2009 |
Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.
Topics: Animals; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Gene Expression; Hydroxyurea; Lipoxygenase Inhibitors; Male; Mouth Neoplasms; Naproxen; Piroxicam; Pyrazoles; Rats; Rats, Inbred F344; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Up-Regulation | 2010 |
The effects of COX-2 inhibitor during osteogenic differentiation of bone marrow-derived human mesenchymal stem cells.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Bone Marrow Cells; Celecoxib; Cell Differentiation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Gene Expression Regulation; Humans; Inflammation; Interleukin-1beta; Male; Mesenchymal Stem Cells; Middle Aged; Naproxen; Osteogenesis; Pyrazoles; RNA, Messenger; Sulfonamides; Young Adult | 2010 |
Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Etoricoxib; Humans; Markov Chains; Meta-Analysis as Topic; Models, Economic; Naproxen; Pyrazoles; Pyridines; Quality-Adjusted Life Years; Severity of Illness Index; Spondylitis, Ankylosing; Sulfonamides; Sulfones; Treatment Outcome; United Kingdom | 2010 |
Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone.
Topics: Aldosterone; Angiotensin II; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Cardiomegaly; Celecoxib; Collagen; Cyclooxygenase 2 Inhibitors; Female; Fibroblasts; Fibrosis; Heart; Hep G2 Cells; Hepatocytes; Humans; Lactones; Male; Myocardium; Myocytes, Cardiac; Naproxen; Pyrazoles; Rats; Renin-Angiotensin System; Sulfonamides; Sulfones; Vasoconstrictor Agents | 2010 |
Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium.
Topics: Angiogenic Proteins; Animals; Apoptosis; Blood Pressure; Celecoxib; Collateral Circulation; Coronary Angiography; Coronary Circulation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Heart Rate; Inflammation Mediators; Microcirculation; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardium; Naproxen; Neovascularization, Physiologic; Oxidative Stress; Prostaglandins; Pyrazoles; Sulfonamides; Swine; Swine, Miniature; Time Factors; Vasoconstrictor Agents; Vasodilator Agents; Ventricular Function, Left | 2010 |
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Confounding Factors, Epidemiologic; Coronary Artery Disease; Diclofenac; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypertension; Ibuprofen; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Myocardial Infarction; Naproxen; Odds Ratio; Proportional Hazards Models; Pyrazoles; Randomized Controlled Trials as Topic; Stroke; Sulfonamides; Verapamil | 2011 |
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bifidobacterium; Celecoxib; Colon; Denaturing Gradient Gel Electrophoresis; Disease Models, Animal; Drug Interactions; Gastrointestinal Hemorrhage; Hematocrit; Jejunum; Lansoprazole; Male; Naproxen; Omeprazole; Peptic Ulcer; Probiotics; Proton Pump Inhibitors; Pyrazoles; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Time Factors | 2011 |
Effects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Heart; Hypercholesterolemia; Male; Myocardial Ischemia; Myocardium; Naproxen; Oxidative Stress; Pyrazoles; Sulfonamides; Swine | 2012 |
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Drug Therapy, Combination; Gastric Mucosa; Gastrointestinal Diseases; Gastrointestinal Tract; Hypertension; Male; Naproxen; Nitrates; Obesity; Omeprazole; Pyrazoles; Rats; Rats, Inbred SHR; Rats, Wistar; Rats, Zucker; Sulfonamides | 2012 |
Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Drug Interactions; Female; Humans; Hypertension; Ibuprofen; Indiana; Linear Models; Male; Middle Aged; Naproxen; Odds Ratio; Propensity Score; Pyrazoles; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Treatment Outcome | 2012 |
How safe is Celecoxib for Asian-Indian patients with rheumatic diseases?
Topics: Adult; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Drug Substitution; Female; Humans; Hypertension; India; Indomethacin; Male; Naproxen; Pyrazoles; Retrospective Studies; Rheumatic Diseases; Sulfonamides; Tertiary Care Centers | 2013 |
Pre-existent asymmetry in the human cyclooxygenase-2 sequence homodimer.
Topics: Acetylation; Amino Acid Sequence; Amino Acid Substitution; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Flurbiprofen; Guanidine; Heme; Humans; Indomethacin; Kinetics; Models, Biological; Mutant Proteins; Mutation; Naproxen; Oxygen; Palmitic Acid; Peroxidase; Protein Multimerization; Pyrazoles; Substrate Specificity; Sulfonamides | 2013 |
More pain for painkillers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Naproxen; Pain; Pyrazoles; Risk Factors; Safety-Based Drug Withdrawals; Sulfonamides; United States; United States Food and Drug Administration | 2013 |
Fluorophore-labeled cyclooxygenase-2 inhibitors for the imaging of cyclooxygenase-2 overexpression in cancer: synthesis and biological studies.
Topics: 4-Chloro-7-nitrobenzofurazan; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fluorescent Dyes; HCT116 Cells; Humans; Ibuprofen; Microscopy, Confocal; Naproxen; Protein Binding; Pyrazoles; Sulfonamides | 2014 |
Biorelevant dissolution of poorly soluble weak acids studied by UV imaging reveals ranges of fractal-like kinetics.
Topics: Celecoxib; Chemistry, Pharmaceutical; Hydrogen-Ion Concentration; Ketoprofen; Kinetics; Microscopy, Electron, Scanning; Naproxen; Powder Diffraction; Pyrazoles; Solubility; Spectrum Analysis, Raman; Sulfathiazole; Sulfathiazoles; Sulfonamides; X-Ray Diffraction | 2014 |
Effects of conventional and hydrogen sulfide-releasing non-steroidal anti-inflammatory drugs in rats with stress-induced and epinephrine-induced gastric damage.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Celecoxib; Disease Models, Animal; Epinephrine; Gastric Mucosa; Hydrogen Sulfide; Lipid Peroxidation; Male; Naproxen; Nitric Oxide; Nitric Oxide Synthase; Pyrazoles; Rats, Wistar; Restraint, Physical; Severity of Illness Index; Stomach Ulcer; Stress, Psychological; Sulfonamides | 2014 |
Evaluation of the diuretic activity in two Mexican medicinal species: Selaginella nothohybrida and Selaginella lepidophylla and its effects with ciclooxigenases inhibitors.
Topics: Animals; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Diuretics; Indomethacin; Male; Mexico; Mice; Naproxen; Plant Extracts; Plants, Medicinal; Potassium; Selaginellaceae; Sodium | 2015 |
Nonsteroidal anti-inflammatory drugs in-vitro and in-vivo treatment and Multidrug Resistance Protein 4 expression in human platelets.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Case-Control Studies; Celecoxib; Cells, Cultured; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Megakaryocytes; Middle Aged; Multidrug Resistance-Associated Proteins; Naproxen; Osteoarthritis; Platelet Activation; Platelet Aggregation; RNA, Messenger | 2016 |
Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Comorbidity; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Health Services Research; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Nonprescription Drugs; Osteoarthritis, Knee; Pain; Pain Measurement; Proton Pump Inhibitors; Quality-Adjusted Life Years; Sensitivity and Specificity; Tramadol; Treatment Outcome; United States | 2016 |
Evidence that diclofenac and celecoxib are thyroid hormone receptor beta antagonists.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Computer Simulation; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Male; Mesenteric Arteries; Models, Molecular; Naproxen; Rats; Rats, Wistar; Thyroid Hormone Receptors beta; Triiodothyronine; Vasodilation | 2016 |
Inflammation: NSAIDs and cardiovascular risk in arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Humans; Ibuprofen; Inflammation; Naproxen; Risk Factors | 2017 |
Therapy: Cardiovascular safety of celecoxib, naproxen and ibuprofen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular System; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Humans; Ibuprofen; Naproxen; Osteoarthritis; Outcome Assessment, Health Care; Safety | 2017 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Humans; Ibuprofen; Naproxen; Pyrazoles; Sulfonamides | 2017 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Humans; Ibuprofen; Naproxen; Pyrazoles; Sulfonamides | 2017 |
NSAIDs for high-risk patients: none, celecoxib, or naproxen?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Ibuprofen; Naproxen; Pyrazoles; Sulfonamides | 2017 |
Therapy: Celecoxib reduces risk of ulcer bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Double-Blind Method; Gastrointestinal Hemorrhage; Humans; Naproxen; Ulcer | 2017 |
[Cardiovascular safety of celecoxib : Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Humans; Ibuprofen; Naproxen; Prospective Studies; Pyrazoles; Sulfonamides | 2017 |
Evaluation of cardiovascular risk associated with SKI306X use in patients with osteoarthritis and rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Cohort Studies; Drugs, Chinese Herbal; Female; Humans; Incidence; Male; Middle Aged; Naproxen; Osteoarthritis; Retrospective Studies; Risk Factors; Time Factors; Young Adult | 2017 |
Non-inferiority versus superiority drug claims: the (not so) subtle distinction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Drug Approval; Drug Therapy; Equivalence Trials as Topic; Humans; Ibuprofen; Models, Statistical; Naproxen; Research Design; Risk Assessment; Risk Factors; Treatment Outcome | 2017 |
Controlled-release nanoencapsulating microcapsules to combat inflammatory diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Capsules; Celecoxib; Cimetidine; Delayed-Action Preparations; Diffusion; Drug Combinations; Drug Compounding; Drug Liberation; Drug Stability; Gastric Juice; Histamine H2 Antagonists; Ibuprofen; Inflammation; Kinetics; Models, Chemical; Nanocapsules; Nanotechnology; Naproxen; Polymers; Solubility; Technology, Pharmaceutical | 2017 |
In high-risk patients with arthritis and previous upper GI bleeding, celecoxib vs naproxen reduced recurrent bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Naproxen; Pyrazoles; Sulfonamides | 2017 |
NSAIDs relieve osteoarthritis (OA) pain, but cardiovascular safety in question even for diclofenac, ibuprofen, naproxen, and celecoxib: what are the alternatives?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Ibuprofen; Naproxen; Network Meta-Analysis; Osteoarthritis; Pain | 2017 |
NSAIDs and cardiac arrest: Non-steroidal anti-inflammatory drug use is associated with increased risk of Out-of-hospital Cardiac Arrest: A nationwide Case-Time-Control study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Denmark; Humans; Ibuprofen; Lactones; Naproxen; Out-of-Hospital Cardiac Arrest; Risk Factors; Sulfones | 2017 |
Safety of non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Celecoxib; Humans; Ibuprofen; Naproxen; Prospective Studies | 2017 |
Penetration and pharmacokinetics of non-steroidal anti-inflammatory drugs in rat prostate tissue.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Celecoxib; Chromatography, Liquid; Comparative Effectiveness Research; Diclofenac; Disease Models, Animal; Ibuprofen; Inflammation; Male; Naproxen; Pelvic Pain; Prostate; Prostatitis; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2018 |
Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular System; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Pharmaceutical; Diclofenac; Female; Hospitalization; Humans; Hypertension; Ibuprofen; Male; Mefenamic Acid; Middle Aged; Naproxen; Risk Factors | 2018 |
Acute pancreatitis with long-term celecoxib vs. ibuprofen or naproxen: data from the PRECISION trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Humans; Ibuprofen; Naproxen; Pancreatitis; Risk; Taiwan | 2018 |
The Aspirin-NSAID Interaction: More Data, But a Lack of Clarity Remains.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Ibuprofen; Naproxen | 2018 |
Editorial: gastrointestinal safety of COX-2 selective and nonselective NSAIDs-the impact of the PRECISION trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Ibuprofen; Naproxen | 2018 |
Editorial: gastrointestinal safety of COX-2 selective and nonselective NSAIDs-the impact of the PRECISION trial. Authors' reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Ibuprofen; Naproxen | 2018 |
Structural efficacy of NSAIDs, COX-2 inhibitor and glucocorticoid compared with TNFα blocker: a study in adjuvant-induced arthritis rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Experimental; Celecoxib; Cyclooxygenase 2 Inhibitors; Etanercept; Glucocorticoids; Hindlimb; Methotrexate; Naproxen; Prednisone; Rats; Treatment Outcome; Tumor Necrosis Factor-alpha | 2019 |
Novel aryl carboximidamide and 3-aryl-1,2,4-oxadiazole analogues of naproxen as dual selective COX-2/15-LOX inhibitors: Design, synthesis and docking studies.
Topics: Animals; Cattle; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Design; Glycine max; Humans; Lipoxygenase Inhibitors; Lymphocytes; Mice; Molecular Docking Simulation; Naproxen; Nitric Oxide Donors; Oxadiazoles | 2019 |
NSAID choice: lessons from PRECISION.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Ibuprofen; Naproxen; Pain; Treatment Outcome | 2019 |
Mitochondrial Permeability Transition Pore Sealing Agents and Antioxidants Protect Oxidative Stress and Mitochondrial Dysfunction Induced by Naproxen, Diclofenac and Celecoxib.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Apoptosis; Celecoxib; Diclofenac; Glutathione; Lipid Peroxidation; Male; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocytes, Cardiac; Naproxen; Oxidative Stress; Protective Agents; Rats; Rats, Wistar; Reactive Oxygen Species | 2019 |
Association between tramadol use and risk of pneumonia in the middle-aged and elderly populations: a propensity-score matched cohort study.
Topics: Aged; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Codeine; Cohort Studies; Diclofenac; Etoricoxib; Humans; Middle Aged; Naproxen; Pneumonia; Tramadol | 2022 |
A comprehensive update on the pharmacological management of heterotopic ossification following hip arthroplasty: a level I evidenced based expert opinion.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Celecoxib; Diclofenac; Expert Testimony; Humans; Naproxen; Ossification, Heterotopic; Postoperative Complications | 2022 |
Design and scale-up of amorphous drug nanoparticles production via a one-step anhydrous continuous process.
Topics: Celecoxib; Drug Carriers; Drug Liberation; Nanoparticles; Naproxen; Particle Size; Pharmaceutical Preparations; Polymethacrylic Acids; Solubility | 2022 |
Gestational NSAIDs distinctly reprogram cardiac injury in preeclamptic rats: Roles of cyclooxygenase, apoptotic and autophagic trails.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Naproxen; Placenta; Pre-Eclampsia; Pregnancy; Rats | 2022 |
The suppression of MAPK/NOX/MMP signaling prompts renoprotection conferred by prenatal naproxen in weaning preeclamptic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Female; Humans; Naproxen; Pre-Eclampsia; Pregnancy; Rats; Vitamins; Weaning | 2023 |